{"pmid":32422207,"title":"Balancing risks and benefits in inflammatory bowel disease patients during the COVID-19 pandemic.","text":["Balancing risks and benefits in inflammatory bowel disease patients during the COVID-19 pandemic.","Gastroenterology","Kotze, Paulo Gustavo","Peyrin-Biroulet, Laurent","Danese, Silvio","32422207"],"journal":"Gastroenterology","authors":["Kotze, Paulo Gustavo","Peyrin-Biroulet, Laurent","Danese, Silvio"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422207","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1053/j.gastro.2020.04.075","topics":["Prevention"],"weight":1,"_version_":1667254896797155328,"score":9.490897,"similar":[{"pmid":32404588,"title":"The timing of labor epidurals in COVID-19 parturients: a balance of risk and benefit.","text":["The timing of labor epidurals in COVID-19 parturients: a balance of risk and benefit.","Anesth Analg","Mullington, Christopher J","Kua, Justin","Malhotra, Surbhi","32404588"],"journal":"Anesth Analg","authors":["Mullington, Christopher J","Kua, Justin","Malhotra, Surbhi"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404588","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1213/ANE.0000000000004974","topics":["Prevention"],"weight":1,"_version_":1666802845435822081,"score":58.626217},{"pmid":32442264,"title":"Labor and Delivery Visitor Policies During the COVID-19 Pandemic: Balancing Risks and Benefits.","text":["Labor and Delivery Visitor Policies During the COVID-19 Pandemic: Balancing Risks and Benefits.","JAMA","Arora, Kavita Shah","Mauch, Jaclyn T","Gibson, Kelly Smith","32442264"],"journal":"JAMA","authors":["Arora, Kavita Shah","Mauch, Jaclyn T","Gibson, Kelly Smith"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442264","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1001/jama.2020.7563","topics":["Prevention"],"weight":1,"_version_":1667535119474229249,"score":58.35138},{"pmid":32355056,"title":"International Organization for the Study of Inflammatory Bowel Disease Recommendations for Surgery in Patients with Inflammatory Bowel Disease During the COVID-19 Pandemic.","text":["International Organization for the Study of Inflammatory Bowel Disease Recommendations for Surgery in Patients with Inflammatory Bowel Disease During the COVID-19 Pandemic.","Dis Colon Rectum","Remzi, Feza H","Panis, Yves","Spinelli, Antonino","Kotze, Paulo G","Mantzaris, Gerassimos","Soderholm, Johan D","d'Hoore, Andre","Bemelman, Willem A","Yamamoto, Takayuki","Pemberton, John","Tiret, Emmanuel","Oresland, Tom","Fleshner, Phillip","32355056"],"journal":"Dis Colon Rectum","authors":["Remzi, Feza H","Panis, Yves","Spinelli, Antonino","Kotze, Paulo G","Mantzaris, Gerassimos","Soderholm, Johan D","d'Hoore, Andre","Bemelman, Willem A","Yamamoto, Takayuki","Pemberton, John","Tiret, Emmanuel","Oresland, Tom","Fleshner, Phillip"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32355056","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1097/DCR.0000000000001718","topics":["Prevention"],"weight":1,"_version_":1666138495255576576,"score":54.638905},{"pmid":32363243,"pmcid":"PMC7194647","title":"Palliative Radiotherapy for Oncologic Emergencies in the setting of COVID-19: Approaches to Balancing Risks and Benefits.","text":["Palliative Radiotherapy for Oncologic Emergencies in the setting of COVID-19: Approaches to Balancing Risks and Benefits.","Adv Radiat Oncol","Yerramilli, Divya","Xu, Amy J","Gillespie, Erin F","Shepherd, Annemarie F","Beal, Kathryn","Gomez, Daniel","Yamada, Josh","Tsai, C Jillian","Yang, T Jonathan","32363243"],"journal":"Adv Radiat Oncol","authors":["Yerramilli, Divya","Xu, Amy J","Gillespie, Erin F","Shepherd, Annemarie F","Beal, Kathryn","Gomez, Daniel","Yamada, Josh","Tsai, C Jillian","Yang, T Jonathan"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363243","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.adro.2020.04.001","topics":["Prevention"],"weight":1,"_version_":1666138496074514433,"score":53.65579},{"pmid":32215548,"pmcid":"PMC7184365","title":"Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","text":["Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","Crohn's disease (CD)] and ulcerative colitis (UC), the main inflammatory bowel diseases (IBD) in human beings, are chronic, immune-inflammatory diseases, whose pathogenesis implicates a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant nowadays, as coronavirus disease (Covid-19) has rapidly spread from China to countries where IBD are more prevalent and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the cells and to illustrate the link between such determinants and the intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk to be infected with SARS-CoV-2 and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia.","J Crohns Colitis","Monteleone, Giovanni","Ardizzone, Sandro","32215548"],"abstract":["Crohn's disease (CD)] and ulcerative colitis (UC), the main inflammatory bowel diseases (IBD) in human beings, are chronic, immune-inflammatory diseases, whose pathogenesis implicates a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant nowadays, as coronavirus disease (Covid-19) has rapidly spread from China to countries where IBD are more prevalent and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the cells and to illustrate the link between such determinants and the intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk to be infected with SARS-CoV-2 and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia."],"journal":"J Crohns Colitis","authors":["Monteleone, Giovanni","Ardizzone, Sandro"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32215548","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1093/ecco-jcc/jjaa061","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490514964482,"score":53.159008}]}